Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 18, 2023 1:26pm

106 Views

Post# 35502490

RE:RE:RE:RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

As already posted :

Pre-clinical CD47 company Trillium Therapeutics was acquired by Pfizer for US2.3 Billion late last year without a 'business deal" being telegraphed beforehand. Comparatively, ONCY is a Phase 3 ready late-stage cancer company that has "de-risked" their immune molecule platform pelareorep asset in mulitple cancers including breast and pancreatic cancer, as examples.

“I think in the late-stage opportunities, there are not that many and it's much more competitive,” said Roche's CEO Thomas Schinecker, Ph.D..

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China